Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 65 (5), 544-9

Progress Made Towards the Development of a CMV Peptide Vaccine


Progress Made Towards the Development of a CMV Peptide Vaccine

S J Paston et al. Hum Immunol.


Cytomegalovirus disease still remains a major cause of morbidity and mortality in hematopoietic stem cell transplantation recipients. The cell-mediated immune response is essential in the maintenance of latency and the resolution of primary infections. The identification of immunodominant cytomegalovirus antigens has enabled researchers to determine the best candidate antigens to be included in a cytomegalovirus vaccine. Such a vaccine would have to stimulate both a cell-mediated and humoral immune response. Recent advances have enabled the rapid identification of minimal cytotoxic epitopes required to trigger such responses. Epitope mapping to date has mainly focused on the pp65 antigen but other antigens such as IE1 are starting to be mapped. A human leukocyte antigen allele hierarchy is starting to emerge that is dependent on the alleles present in an individual; this is relevant when considering what peptides should be included in a vaccine. This review looks at the current methods available for epitope mapping and the progress that has been made to date.

Similar articles

See all similar articles

Cited by 6 articles

See all "Cited by" articles

MeSH terms

LinkOut - more resources